John Connolly, President and Chief Executive Officer of Rna Diagnostics is pleased to announce the appointment of Dr. Stefan Glück, MD, PhD, FRCCP to the position of Chief Medical Officer. Dr. Glück has had a distinguished career in breast cancer treatment and research as an academic medical oncologist, researcher and biotech industry executive.
Rna Diagnostics is a cancer diagnostics company developing a platform of predictive biomarker tools to help improve the lives of cancer patients. Rna Diagnostics’ first product is the RNA Disruption Assay™. The RNA Disruption Assay™ (RDA™) an evaluation of how individual patients are responding to drug therapy as early as one month after initiation of treatment.
“I am extremely pleased and humbled to be able to join this amazing team. They have developed a potentially paradigm changing test for early breast cancer and maybe beyond,” said Dr. Glück.
Dr. Glück is a medical oncologist licensed in the USA, Germany, and Canada. He served as a Sylvester Professor and practicing Medical Oncologist – Hematologist in the Department of Medicine at the Miller School of Medicine, University of Miami, Florida where he was the Clinical Director of the Braman Family Breast Cancer Institute. His clinical practice focused on patients with breast cancer and during his hospital service, all malignant diseases including hematology and solid tumors. Dr. Glück was Director for the Southern Alberta Breast Cancer Program at the Tom Baker Cancer Centre; a professor in the Departments of Oncology, Medicine, Pharmacology, and Therapeutics at the University of Calgary in Alberta, Canada; and Deputy Head of the Department of Oncology at the University of Calgary.
Dr Glück is expert in breast cancer clinical trials. He was principal investigator in more than 30 clinical studies in breast cancer during his career at University of Miami. He has authored or co-authored over 275 Scientific articles on cancer. In addition to his clinical practice and research, Dr. Glück has served as a reviewer for cancer journals such as the Journal of Clinical Oncology, European Journal of Cancer, Lancet Oncology, Lancet, Breast Cancer Research, The Oncologist, The Breast Journal, Clinical Breast Cancer, and many others. He was medical associate editor of Breast Cancer Research and Treatment and co-editor in chief of the Journal of Carcinogenesis.
Dr. Glück joined Celgene Corporation as Vice President, Global Medical Affairs in 2014 where he oversaw oncology activities worldwide, as well as Celgene’s Immune-Oncology program in solid tumors and hematology. He was part of the very successful business development team that identified partners for collaboration, joint venture, and acquisition. In 2020, after Celgene was acquired by BMS he joined Regeneron Pharmaceuticals as Vice President and Franchise Head, Global Medical Affairs, Oncology / Hematology.
“Dr. Glück brings a wealth of academic and scientific experience in medical oncology to the Rna Diagnostics executive team. He also brings well developed practical commercialization expertise that will be critical to our success as we introduce the RNA Disruption Assay into clinical practice in North America and Europe. We are honoured to have Dr. Glück join Rna Diagnostics,” said John Connolly.
For more information please contact
John Connolly, President & CEO
About Rna Diagnostics Inc.
Rna Diagnostics is a cancer diagnostics company developing a platform of predictive biomarker tools to help improve the lives of cancer patients. Founded in 2010, Rna Diagnostics’ first product is the RNA Disruption Assay™. The RNA Disruption Assay™ (RDA™) provides an evaluation of how individual patients are responding to drug therapy as early as one month after initiation of treatment. If chemotherapy is working, the physician and patient can continue treatment with confidence. If chemotherapy is not working, physicians may consider alternate therapies. For patients, this means avoiding harmful side effects of ineffective treatments and the possibility for improved survival outcomes. www.rnadiagnostics.com.